Advaxis to Present an Overview of its Lm Platform and New Information on its Neoantigen-Directed Therapy Programs at the Immuno-Oncology 360° Conference

 
 
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that an overview of the Company’s proprietary Lm platform and new information regarding the Company’s neoantigen-directed therapy programs, ADXS-NEO (customized, personalized neoantigens) and ADXS-HOT (off-the-shelf, hotspot or shared neoantigens and other antigens), will be presented during a plenary session at the Immuno-Oncology 360° conference on February 6, 2019. The conference is being held at the Crowne Plaza Times Square in New York City; the plenary session begins at 4:00 p.m. ET and the Advaxis presentation is scheduled to begin at 4:40 p.m. ET.

The presentation will be made by Andres A. Gutierrez, M.D., Ph.D., Chief Medical Officer and Executive Vice President of Advaxis, and Robert G. Petit, Ph.D., Chief Scientific Officer and Executive Vice President of Advaxis. Advaxis intends to issue a news release on February 6, 2019, that summarizes the presentation by Drs. Gutierrez and Petit.

ADXS-NEO, the Company’s personalized neoantigen program, is in an ongoing Phase 1 dose-escalation study to treat a variety of cancers. ADXS-HOT is the Company’s off-the-shelf program and consists of several different drug constructs which target hotspot or shared neoantigens, and other antigens. The first drug construct from this program is ADXS-503, or HOT-Lung, for the treatment of non-small cell lung cancer. ADXS-503 is expected to enter the clinic this quarter.

About Advaxis, Inc.

Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, personalized neoantigen-directed immunotherapy, off-the-shelf, hotspot/cancer antigens neoantigen-directed immunotherapy and prostate cancer.

To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.

 

Contacts

Investors:
LHA Investor Relations
Miriam Weber Miller, (212) 838-3777
mmiller@lhai.com

 
 

Source: Advaxis, Inc.

Back to news